Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for breast cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Contemporary Hormonal Contraception and the Risk of BreastCancer. BACKGROUND: Little is known about whether contemporary hormonal contraception is associated with an increased risk of breastcancer. METHODS: We assessed associations between the use of hormonal contraception and the risk of invasive breastcancer in a nationwide prospective cohort study involving all women in Denmark between 15 and 49 years of age who had not had cancer or venous thromboembolism and who had not received (...) treatment for infertility. Nationwide registries provided individually updated information about the use of hormonal contraception, breast-cancer diagnoses, and potential confounders. RESULTS: Among 1.8 million women who were followed on average for 10.9 years (a total of 19.6 million person-years), 11,517 cases of breastcancer occurred. As compared with women who had never used hormonal contraception, the relative risk of breastcancer among all current and recent users of hormonal contraception was
A feasibility study of neoadjuvant talazoparib for operable breastcancer patients with a germline BRCAmutation demonstrates marked activity ARTICLE OPEN A feasibility study of neoadjuvant talazoparib for operable breastcancer patients with a germlineBRCA mutation demonstrates marked activity J. K. Litton 1 , M. Scoggins 2 , D. L. Ramirez 1 , R. K. Murthy 1 , G. J. Whitman 2 , K. R. Hess 3 , B. E. Adrada 2 , S. L. Moulder 1 , C. H. Barcenas 1 , V. Valero 1 , J. Schwartz Gomez 1 , E (...) . A. Mittendorf 4 , A. Thompson 4 , T. Helgason 1 , G. B. Mills 5 , H. Piwnica-Worms 6 and B. K. Arun 1 This study was undertaken to determine the feasibility of enrolling breastcancer patients on a single-agent-targeted therapy trial before neoadjuvant chemotherapy. Speci?cally, we evaluated talazoparib in patients harboring a deleterious BRCAmutation (BRCA +). Patients with a germline BRCAmutation and=1cm, HER2-negative primary tumors were eligible. Study participants underwent a pretreatment biopsy, 2
Fulvestrant (Faslodex) - Treatment of oestrogen receptor positive, locally advanced or metastaticbreastcancer Published 11 December 2017 Statement of Advice: fulvestrant 250 mg solution for injection (Faslodex ® ) SMC No 1294/17 AstraZeneca UK Limited 10 November 2017 ADVICE: in the absence of a submission from the holder of the marketing authorisation fulvestrant (Faslodex ® ) is not recommended for use within NHS Scotland. Indication under review: Treatment of oestrogen receptor positive (...) , locally advanced or metastaticbreastcancer in postmenopausal women not previously treated with endocrine therapy. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland. Advice context: No part of this advice may be used without the whole of the advice being quoted in full. This advice represents the view of the Scottish Medicines Consortium. It is provided to inform
Role of Bone-Modifying Agents in MetastaticBreastCancer: An American Society of Clinical Oncology?Cancer Care Ontario Focused Guideline Update | Cancer Care Ontario Google Tag Manager You are using an outdated browser. We suggest you update your browser for a better experience. for update. Browse Guidelines Browse Pathway Maps Sort by You are here / / Role of Bone-Modifying Agents in MetastaticBreastCancer: An American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline (...) Update Guidelines & Advice Role of Bone-Modifying Agents in MetastaticBreastCancer: An American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline Update ID: GL-1-A-2016-2 Oct 2017 Type of Content: Guidelines & Advice, Clinical Document Status: Current Authors: Catherine Van Poznak, Mark R. Somerfield, William E. Barlow, J. Sybil Biermann, Linda D. Bosserman, Mark J. Clemons, Sukhbinder K. Dhesy-Thind, Melissa S. Dillmon, Andrea Eisen, Elizabeth S. Frank, Reshma Jagsi, Rachel
Effect of myofascial techniques for treatment of persistent arm pain after breastcancer treatment: randomized controlled trial 28914087 2017 09 15 1477-0873 2017 Sep 01 Clinical rehabilitation Clin Rehabil Effect of myofascial techniques for treatment of persistent arm pain after breastcancer treatment: randomized controlled trial. 269215517730863 10.1177/0269215517730863 To investigate the effect of myofascial therapy in addition to a standard physical therapy program for treatment (...) of persistent arm pain after finishing breastcancer treatment. Double-blinded (patient and assessor) randomized controlled trial. University Hospitals Leuven, Belgium. A total of 50 patients with persistent arm pain and myofascial dysfunctions after breastcancer treatment. Over three months, all patients received a standard physical therapy program. The intervention group received in addition 12 sessions of myofascial therapy, and the control group received 12 sessions of placebo therapy. Main outcome
Bevacizumab (Kyomarc) - for the treatment of cancer of the colon or rectum, breastcancer, non-small cell lung cancer (NSCLC), kidney cancer, cervical cancer, and cancer of the ovary, the fallopian tube, or the peritoneum.
Mesenchymal stem cells in breastcancer: response to chemical and mechanical stimuli 158 www.impactjournals.com/oncoscience Oncoscience www.impactjournals.com/oncoscience/ Oncoscience, Vol. 4(11-12), November 2017 Mesenchymal stem cells in breastcancer: response to chemical and mechanical stimuli Seiichiro Ishihara, Suzanne M. Ponik, and Hisashi Haga The tumor microenvironment contains not only cancer cells but also non-cancerous cells and extracellular matrices (ECMs). These cell types (...) interact through chemical and mechanical stimuli and as a result, regulate tumor progression. While many studies have identified chemical stimuli that are critical for cancer progression, the role of mechanical stimuli is less defined. It has been recently shown that mechanical stimuli, especially the stiffness of ECMs, contribute to tumor progression in some specific cancers including breast, colorectal, and lung [1, 2, 3]. In particular, cancer cells respond to stiffness of surrounding ECMs
Molecular changes in premenopausal oestrogen receptor-positive primary breastcancer in Vietnamese women after oophorectomy ARTICLE OPEN Molecular changes in premenopausal oestrogen receptor- positive primary breastcancer in Vietnamese women after oophorectomy Ben P. Haynes 1 , Ophira Ginsburg 2,3 , Qiong Gao 4 , Elizabeth Folkerd 1 , Maria Afentakis 1 , Le Hong Quang 5 , Pham Thi Han 6 , Pham Hong Khoa 5 , Nguyen Van Dinh 5 ,TaVanTo 6 , Mark Clemons 7 , Ian E. Smith 8 and Mitch Dowsett 1,4 (...) For premenopausal women with primary ER+breastcancer, oophorectomy (OvX) is an evidence-based cost-effective option and is standard treatment in many countries. However, there is virtually no data describing the effects of OvX on breasttumour biology. We therefore, characterised the endocrine and genome-wide transcriptional impact of OvX in 56 premenopausal women with ER+ breastcancerfor2weekspriortomastectomy.Plasmaestradiolconcentrationsdecreasedfrom406±41to20.7±2.6pmol/l(mean ±sem) 24h after OvX
PTK6 regulates growth and survival of endocrine therapy-resistant ER+ breastcancer cells ARTICLE OPEN PTK6 regulates growth and survival of endocrine therapy- resistant ER+ breastcancer cells Koichi Ito 1 , Sun Hee Park 1 , Igor Katsyv 2 , Weijia Zhang 3 , Carmine De Angelis 4,5 , Rachel Schiff 4,5,6 and Hanna Y. Irie 1,7 The non-receptor tyrosine kinase, PTK6/BRK, is highly expressed in multiple tumor types, including prostate, ovarian, and breastcancers, and regulates oncogenic phenotypes (...) such as proliferation, migration, and survival. PTK6 inhibition also overcomes targeted therapy resistance of HER2+ breastcancer. Although PTK6 is highly expressed in ER+ Luminal breastcancers, the role of PTK6 in this subtype has not been elucidated. In this study, we investigated the functions of PTK6 in ER+ Luminal breastcancer cells, including those that are relatively resistant to estrogen deprivation or targeted endocrine therapies used in the treatment of ER+ cancers. Enhanced expression of PTK6 in ER
Psychometric properties of the Beliefs about Medicine Questionnaireâ€“adjuvant endocrine therapy (BMQ-AET) for women taking AETs following early-stage breastcancer SAGE Journals: Your gateway to world-class journal research MENU Sign In Institution Society Access Options You can be signed in via any or all of the methods shown below at the same time. My Profile Sign in here to access free tools such as favourites and alerts, or to access personal subscriptions Email (required) Password
A metastasis biomarker (MetaSite Breastâ„¢ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breastcancer ARTICLE OPEN A metastasis biomarker (MetaSite Breast™ Score) is associated with distant recurrence in hormone receptor- positive, HER2-negative early-stage breastcancer Joseph A. Sparano 1 , Robert Gray 2 , Maja H. Oktay 1 , David Entenberg 3 , Thomas Rohan 3 , Xiaonan Xue 3 , Michael Donovan 4 , Michael Peterson 5 , Anthony Shuber 5 (...) for tumor cells into the circulation. We evaluated primary tumors from 600 patients with Stage I–III breastcancer treated with adjuvant chemotherapy in trial E2197 (NCT00003519), plus endocrine therapy for hormone receptor (HR)+ disease. TMEM were identi?ed and enumerated using an analytically validated, fully automated digital pathology/image analysis method (MetaSite Breast™), hereafter referred to as MetaSite Score (MS). The objectives were to determine the association between MS and distant relapse
Author Correction: The contribution of pathogenic variants in breastcancer susceptibility genes to familial breastcancer risk 29119134 2017 12 19 2374-4677 3 2017 NPJ breastcancer NPJ BreastCancer Erratum: Author Correction: The contribution of pathogenic variants in breastcancer susceptibility genes to familial breastcancer risk. 44 10.1038/s41523-017-0046-2 [This corrects the article DOI: 10.1038/s41523-017-0024-8.]. Slavin Thomas P TP Department of Medical Oncology, Division (...) .410425.6 Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA USA. 0000 0004 0421 8357 grid.410425.6 Couch Fergus J FJ Department of Health Sciences Research, Mayo Clinic, Rochester, MN USA. 0000 0004 0459 167X grid.66875.3a Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN USA. 0000 0004 0459 167X grid.66875.3a eng Published Erratum 2017 11 07 United States NPJ BreastCancer 101674891 2374-4677 NPJ BreastCancer. 2017 Jun 9;3:22 28649662